|Bid||2.410 x 39400|
|Ask||2.430 x 1400|
|Day's Range||2.4200 - 2.4300|
|52 Week Range||0.9920 - 2.7000|
|Beta (3Y Monthly)||1.44|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 12, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.48|
BALA CYNWYD, PA / ACCESSWIRE / February 18, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of CAS Medical Systems, Inc. ("CAS ...
NEW ORLEANS , Feb. 15, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale ...
NEW YORK , Feb. 15, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of CAS Medical Systems, Inc. ("CASM" ...
NEW YORK , Feb. 14, 2019 /PRNewswire/ -- CAS Medical Systems, Inc. (CASM) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of CASM ...
NEW YORK, Feb. 12, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of CAS Medical Systems, Inc. (NASDAQ: CASM) on.
NEW YORK , Feb. 12, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against CAS Medical Systems, Inc. (NASDAQ: CASM) and its board of directors for breach of fiduciary duty concerning ...
Companies working in the healthcare sector are tasked with meeting the growing demand for effective treatment options given that, almost every day, medical experts discover a new disease or ailment. Premier Health Group (OTC:PHGRF) (CSE:PHGI), CAS Medical Systems Inc (CASM), CorMedix Inc (NYSE American: CRMD), and Viking Therapeutics Inc (VKTX) represent four healthcare companies determined to create products to help consumers have a better life.
CAS Medical is a medical tech company that focuses on non-invasive monitoring of tissue oxygenation in the brain. Edwards will buy CAS Medical in an all-cash transaction for $2.45 per share, or an equity value of about $100 million, according to the terms of the deal.
NEW YORK, Feb. 12, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased CAS Medical Systems, Inc. (“CASMED”.
Shares of CAS Medical Systems Inc. rocketed 54% toward a six-month high in morning trade Tuesday, enough to pace all Nasdaq gainers, after the medical technology company agreed to be acquired by Edwards Lifesciences Corp. in a cash deal valued at $100 million. Under terms of the deal, Edwards will pay $2.45 for each CAS share outstanding, which is 56% above Monday's closing price of $1.57. The deal price implies a $70.7 million market capitalization for CAS. Edwards' stock tacked on 0.7%. "Cerebral oximetry technology provides an important indicator of oxygen levels in the brain, which can enhance clinician decision-making, said Katie Szyman, vice president of critical care at Edwards. "We believe the incorporation of CASMED's FORE-SIGHT technology into Edwards' leading hemodynamic monitoring platform, along with Edwards' predictive analytics capability, will strengthen Edwards' leadership in smart monitoring technologies by providing physicians with a more comprehensive status of their surgical and critically ill patients." CAS shares have not run up 28% over the past three months and Edwards' stock has rallied 18%, while the S&P 500 has gained 0.1%.
IRVINE, Calif. and BRANFORD, Conn., Feb. 12, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has entered into a definitive merger agreement to acquire CAS Medical Systems, Inc. (CASM) (CASMED), a medical technology company dedicated to non-invasive monitoring of tissue oxygenation in the brain. "Cerebral oximetry technology provides an important indicator of oxygen levels in the brain, which can enhance clinician decision-making," said Katie Szyman, Edwards' corporate vice president, critical care.
Tom Patton became the CEO of CAS Medical Systems, Inc. (NASDAQ:CASM) in 2010. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
Post-market close yesterday, CAS Medical (CASM) released preliminary Q4 revenue and monitor placement numbers and provided initial (general) guidance for how they think 2019 may shape up. Note, however, that this current 2019 guidance, of low double-digit FORE-SIGHT sales growth (inline with our prior and current estimates), does not include any potential contribution from their OEM smart cable product – which management now thinks will launch around mid-year. Company guidance will be updated following the launch.
CAS Medical Systems, Inc. (CASM) (CASMED), a leader in non-invasive cerebral oximetry patient monitoring, reports preliminary unaudited topline results for the three and 12 months ended December 31, 2018. The Company expects net sales from continuing operations for the fourth quarter of 2018 to be approximately $5.8 million, up 13% from $5.1 million for the fourth quarter of 2017. Net sales from continuing operations for 2018 are expected to be approximately $21.9 million, up 17% from $18.8 million for 2017.
In this article I am going to calculate the intrinsic value of CAS Medical Systems Inc (NASDAQ:CASM) by estimating the company’s future cash flows and discounting them to their present Read More...
Another solid quarter turned in by CAS Medical (CASM) with total revenue jumping 19% yoy and about 2% better than Q2. The combination of revenue growth and effective expense-control initiatives have pushed operating loss lower by an average of ~$150k each quarter since Q1 2017. Importantly, despite the recently instituted trade tariffs, management is guiding for reaching cash flow break even by the end of 2019 (and possibly sooner if the tariffs are lifted).
Junior miners turned lower in sympathy with declining gold and silver contracts, while small biotech and medical diagnostic stocks picked up the slack, underpinned by sector funds probing new highs. September has a mixed reputation when it comes to small speculative plays, suggesting that traders focus their attention on penny stocks exhibiting the highest relative strength while avoiding falling knives that may face tax selling pressure in the fourth quarter. Low-priced energy stocks look like wild cards in this equation, with crude oil coming off lows while rising Middle East tensions add to sector buying power.
The FORE-SIGHT business, particularly as it relates to the U.S. market, continues to impress. The U.S. installed base expanded by 25% yoy during the first half of 2018 and domestic sensor sales have now set new record highs for three consecutive quarters. U.S. FORE-SIGHT revenue grew by an average of 20% yoy over the last three quarters (including 20% in Q2).